Company Profiles

driven by the PitchBook Platform

CalciMedica

Description

Developer of therapeutic novel drugs designed to treat acute immune disorders. The company's therapeutic novel drugs are specific inhibition of the calcium release-activated calcium (CRAC) channel, a key component of the Icrac pathway in immune cells, enabling healthcare professionals to treat acute and chronic inflammatory and immune disorders, and organ transplant rejection.

2006

Founded

PRIVATE

Status

11-50

Employees

Series A

Latest Deal Type

$5.5M

Latest Deal Amount

$63.8M

Total Amount Raised

Description

Developer of therapeutic novel drugs designed to treat acute immune disorders. The company's therapeutic novel drugs are specific inhibition of the calcium release-activated calcium (CRAC) channel, a key component of the Icrac pathway in immune cells, enabling healthcare professionals to treat acute and chronic inflammatory and immune disorders, and organ transplant rejection.

Website:

www.calcimedica.com

Ownership Status

Privately Held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Pharmaceuticals

Other Industries

Drug Discovery

Primary Office

505 Coast Boulevard South Suite 202 San Diego, CA 92037United States +1 (858) 952-5500
    Request a free trial to the PitchBook Platform
    You're viewing a free company profile from the PitchBook Platform. To explore CalciMedica's full profile, request a free trial.

    CalciMedica Valuation and Funding

    Request access
    Deal TypeDateAmountRaised to DatePost-ValStatusStage

    CalciMedica Cap Table

    Stock# of Shares
    Authorized
    Par ValueDividend Rate (%)Original
    Issue Price
    LiquidationLiquidation
    Pref. Multiple
    Conversion
    Price
    % Owned

    CalciMedica Investors (6)

    Request access
    Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
    Seat
    Contact
    Info
    BiogenPE-Backed CompanyMinority000 0000000 0000
    CONNECT (Accelerator)Accelerator/Incubator000 0000000 0000
    Individual InvestorAngel (individual)Minority000 0000000 0000
    Raptor PharmaceuticalsCorporationMinority000 0000000 0000
    Sanderling VenturesVenture CapitalMinority000 0000000 0000
    Biogen PE-Backed Company
    CONNECT (Accelerator) Accelerator/Incubator
    Individual Investor Angel (individual)
    Raptor Pharmaceuticals Corporation
    Sanderling Ventures Venture Capital

    CalciMedica Executive Team (8)

    NameTitleBoard
    Seat
    Contact
    Info
    Michael DunnPresident & Chief Operating Officer
    Kenneth Stauderman Ph.DCo-Founder & Chief Scientific Officer
    Anjana Rao Ph.DCo-Founder & Scientific Advisor
    Patrick Hogan Ph.DCo-Founder & Scientific Advisor
    Stefan Feske MDCo-Founder & Scientific Advisor
    Michael Dunn President & Chief Operating Officer
    Kenneth Stauderman Ph.D Co-Founder & Chief Scientific Officer
    Anjana Rao Ph.D Co-Founder & Scientific Advisor
    Patrick Hogan Ph.D Co-Founder & Scientific Advisor
    Stefan Feske MD Co-Founder & Scientific Advisor

    CalciMedica Board Members (6)

    NameRepresentingRoleSinceContact
    Info
    Brian Gallagher Ph.DSR OnePartner000 0000
    Evelyn GrahamSelfBoard Member000 0000
    John McDonaldSelfBoard Member000 0000
    Peter McWilliams Ph.DSanderling VenturesManaging Director000 0000
    Timothy WollaegerSanderling VenturesManaging Director000 0000
    Brian Gallagher Ph.D Partner SR One
    Evelyn Graham Board Member Self
    John McDonald Board Member Self
    Peter McWilliams Ph.D Managing Director Sanderling Ventures
    Timothy Wollaeger Managing Director Sanderling Ventures
    Request full access to PitchBook